# US 2013/0253067 A1 · Method of treating bladder disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253067 A1
- Document ID: US20130253067A1
- Status: Published application
- Kind: A1
- Application number: 13/798,248
- Filed: 2013-03-13
- Published: 2013-09-26
- Earliest claimed: 2012-03-23
- Assignees: Targacept, Inc.
- Applicants: Targacept, Inc.
- Inventors: Merouane Bencherif; Steven M. Toler
- Web page: https://patentgrep.com/patent/US20130253067A1

## CPC

- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61P 31/10: Antimycotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of bladder disorders, including overactive bladder.

## Claims

### Claim 1

A method of treating overactive bladder, the method comprising the administration of a therapeutically effective amount of dexmecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine, to a subject with overactive bladder.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the administration of dexmecamylamine is sufficient to increase the micturition interval relative to baseline in the subject in need thereof.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the administration of dexmecamylamine is sufficient to increase the micturition interval by at least 10% relative to baseline in the subject in need thereof.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the administration of dexmecamylamine is sufficient to increase the micturition interval by at least 10% relative to baseline without significant detrimental changes in bladder contraction amplitude in the subject in need thereof.

### Claim 5

A method of treating overactive bladder, the method comprising the oral administration of dexmecamylamine or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg to about 2.0 mg BID, substantially free of exo-R-mecamylamine, to a subject with overactive bladder.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the oral administration of dexmecamylamine is sufficient to increase the micturition interval by at least 10% relative to baseline in the subject in need thereof.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 0.5 mg BID.

### Claim 8 (depends on 5)

The method according to claim 5, wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 1.0 mg BID.

### Claim 9 (depends on 5)

The method according to claim 5, wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 2.0 mg BID.

### Claim 10 (depends on 5)

The method according to claim 5, wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in tablet form.

### Claim 11 (depends on 5)

The method according to claim 5, wherein the administration of dexmecamylamine is sufficient to increase the micturition interval by at least 10% relative to baseline without significant detrimental changes in bladder contraction amplitude in the subject in need thereof.

### Claim 12 (depends on 1)

The method according to claim 1, wherein the administration of dexmecamylamine or a pharmaceutically acceptable salt thereof is sufficient to increase mean voided volume per micturition relative to baseline.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the administration of dexmecamylamine or a pharmaceutically acceptable salt thereof is sufficient to increase mean voided volume per micturition by at least 10% relative to baseline.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the administration of dexmecamylamine or a pharmaceutically acceptable salt thereof is sufficient to increase bladder capacity relative to baseline.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the administration of dexmecamylamine or a pharmaceutically acceptable salt thereof is sufficient to increase bladder capacity by at least 10% relative to baseline.

### Claim 16

A method of treating overactive bladder, the method comprising the administration of a therapeutically effective amount of dexmecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine, to a subject with overactive bladder, wherein the administration of dexmecamylamine is sufficient to achieve a reduction of at least about 0.6 micturitions per twenty-four hours relative to baseline in the subject in need thereof.

### Claim 17 (depends on 16)

The method according to claim 16, wherein the administration of dexmecamylamine is sufficient to achieve a reduction of at least about 0.8 micturitions per twenty-four hours relative to baseline without inducing dry mouth in the subject in need thereof.

### Claim 18 (depends on 16)

The method according to claim 16, wherein the administration of dexmecamylamine is sufficient to achieve a reduction of at least about 1.0 micturitions per twenty-four hours relative to baseline in the subject in need thereof.

### Claim 19 (depends on 16)

The method according to claim 16, wherein the administration of dexmecamylamine is sufficient to achieve a reduction of at least about 1.2 micturitions per twenty-four hours relative to baseline in the subject in need thereof.

### Claim 20 (depends on 16)

The method according to claim 16, wherein the administration of dexmecamylamine is sufficient to achieve a reduction of at least about 1.4 micturitions per twenty-four hours relative to baseline in the subject in need thereof.

### Claim 21

A method of treating overactive bladder in a subject, the method comprising the oral administration of dexmecamylamine or a pharmaceutically acceptable salt thereof in an amount from about 0.1 mg to about 2.0 mg BID, substantially free of exo-R-mecamylamine, to the subject with overactive bladder, wherein the administration of dexmecamylamine is sufficient to achieve a reduction of at least about 0.6 micturitions per twenty-four hours relative to baseline in the subject in need thereof.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the oral administration of dexmecamylamine is sufficient to achieve a reduction of at least about 0.8 micturitions per twenty-four hours relative to baseline in the subject in need thereof.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the oral administration of dexmecamylamine is sufficient to achieve a reduction of at least about 1.0 micturitions per twenty-four hours relative to baseline in the subject in need thereof.

### Claim 24 (depends on 21)

The method according to claim 21, wherein the oral administration of dexmecamylamine is sufficient to achieve a reduction of at least about 1.2 micturitions per twenty-four hours relative to baseline in the subject in need thereof.

### Claim 25 (depends on 21)

The method according to claim 21, wherein the oral administration of dexmecamylamine is sufficient to achieve a reduction of at least about 1.4 micturitions per twenty-four hours relative to baseline in the subject in need thereof.

### Claim 26 (depends on 21)

The method according to claim 21, wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 0.5 mg BID.

### Claim 27 (depends on 21)

The method according to claim 21, wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 1.0 mg BID.

### Claim 28 (depends on 21)

The method according to claim 21, wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in an amount of about 2.0 mg BID.

### Claim 29 (depends on 21)

The method according to claim 21, wherein the dexmecamylamine or a pharmaceutically acceptable salt thereof is orally administered in tablet form.

### Claim 30 (depends on 1)

The method according to claim 1, wherein the subject is a human.
